Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index: related news

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data PHILADELPHIA, May 16 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has further increased coverage of the growing patent activity in the Asia Pacific region with the addition of registered Japanese Utility Models in Derwent World Patents Index(R) (DWPI(SM)). This is the latest addition to the DWPI database, with Chinese Utility Model Registrations added in October 2007. The inclusion of the Japanese Utility Models provides the best access to Asian patents in English, and further enhances the value of DWPI for prior art and patentability searches.

Thomson Reuters Expands Japanese Patent Coverage

Thomson Reuters, a source of information for businesses and professionals, has added a registered Japanese Utility Models in Derwent World Patents Index (DWPI), a database of patent documents. The inclusion of the Japanese Utility Models provides access to Asian patents in English. Japanese Utility Models can be used to seek protection for devices that have a short lifecycle, or for inventions that have a lower technological aspect when compared to a full patent.

Thomson Reuters Expands Japanese patent coverage

(MENAFN - Asia Pulse) Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has further increased coverage of the growing patent activity in the Asia Pacific region with the addition of registered Japanese Utility Models in Derwent World Patents Index(R) (DWPI(SM)).

U.S. Patent Office allows another significant VNUS patent

Add our medical news to digg - U.S. Patent Office allows another significant VNUS patent Add our medical news to NewsVine - U.S. Patent Office allows another significant VNUS patent Add our medical news to Fark - U.S. Patent Office allows another significant VNUS patent Add our medical news to Furl - U.S. Patent Office allows another significant VNUS patent Add our medical news to Shadows - U.S. Patent Office allows another significant VNUS patent Add our medical news to YahooMyWeb - U.S. Patent Office allows another significant VNUS patent Add our medical news to Reddit -U.S. Patent Office allows another significant VNUS patent Add our medical news to StumbleUpon - U.S. Patent Office allows another significant VNUS patent Add our medical news to Facebook - U.

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Addition of English-translated Japanese Utility Models Provides Most Comprehensive Access to Proliferating Asian Patent Data PHILADELPHIA, May 16

Thomson Reuters Expands Japanese Patent Coverage in Derwent World Patents Index

Alcohol/Substance Abuse & Dependency; Evaluation and Management 2nd Edition - 2007 Update is a Clinical Guideline for the Screening, Evaluation and Management of Alcohol and Substance Abuse Disord

STN AnaVist, Version 2.0, Offers Access to Patent Data

Chemical Abstracts Service (CAS), a division of the American Chemical Society (ACS), and FIZ Karlsruhe announce a new version of STN AnaVist analysis and visualization software. The newest version features Derwent World Patents Index (DWPI), along with new developments in functionality that address customers' most requested enhancements. DWPI from Thomson Scientific is a database of value-added patent information. STN AnaVist works with STN Express, Version 8.2, to analyze content from STN, an online service for science and technology. Now, in addition to analyzing search results from the multidisciplinary CAplus database and the patent databases USPATFULL and PCTFULL, the new version of STN AnaVist analyzes content from Derwent World Patents Index (DWPI), a database providing information on patent publications from patent-issuing authori

Thomson Reuters Publishes 'World IP Today' Report, Analyzing Global Patent Activity and Technology Innovations in 2007

LONDON, May 5 /PRNewswire-FirstCall/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today published two issues of World IP Today, analyzing global patent activity and technology innovations for the year 2007. Both reports draw on data mined from Thomson Innovation(SM), the new standard in IP research and analysis, and give a highly detailed view of recent IP developments across the globe.

International Companies Require China-Specific Patent Strategies

Shanghai, China – May 22, 2008: China, one of the world’s largest and most promising markets, has seen a 20 percent annual increase in patent application filings over the last fifteen years. In 2007, the State Intellectual Property Office (SIPO) of China received 694,153 patent applications, an increase of 21.1 percent over the previous year. These applications included filings for all three types of patents granted in China: Invention patents (valid for 20 years from the date of filing), Utility Models (valid for 10 years), and Design patents (also valid for 10 years). With regard to invention patents (20 year patents), China is currently third in the world behind the United States and Japan. In its latest study, Evalueserve, a global research and analytics firm, forecasts that if patent filings in China continue to grow at the current r

Tech Companies Team Up To Buy Up Patents To Keep Them Away From Others

Google, Verizon, HP, Cisco and some others are apparently teaming up to put money towards buying patents to keep them out of the hands of patent hoarders who would turn around and sue them. This isn't a new concept, and has been tried before -- and it didn't help much. The problem is that many of the worst patent suits aren't from "known" patents, but someone claiming a patent on some minor feature that everyone thought was obvious. Also, this type of action only encourages more bad patent activities by adding another buyer to the market. Now, questionable patent holders will recognize that they can also just sell to this patent pool, rather than selling to some patent hoarding firm. This is one of those ideas that sounds good on paper, but will have little to no effect on slowing down or stopping bad patent lawsuits, and may actually enc

U.S. Patent Office Upholds One of Four Patents on Viread

Gilead Sciences on Tuesday announced that the U.S. Patent and Trademark Office upheld one of four patents on its antiretroviral drug Viread, Reuters reports. The four patents had been challenged by the not-for-profit group Public Patent Foundation, or PUBPAT, last year. PTO has not ruled on the remaining three patents, according to Reuters (Beasley, Reuters, 5/20).

Telik announces patents on TELINTRA compounds

Add our medical news to digg - Telik announces patents on TELINTRA compounds Add our medical news to NewsVine - Telik announces patents on TELINTRA compounds Add our medical news to Fark - Telik announces patents on TELINTRA compounds Add our medical news to Furl - Telik announces patents on TELINTRA compounds Add our medical news to Shadows - Telik announces patents on TELINTRA compounds Add our medical news to YahooMyWeb - Telik announces patents on TELINTRA compounds Add our medical news to Reddit -Telik announces patents on TELINTRA compounds Add our medical news to StumbleUpon - Telik announces patents on TELINTRA compounds Add our medical news to Facebook - Telik announces patents on TELINTRA compounds

Barr confirms patent challenge of Prevacid SoluTab tablets

Add our medical news to digg - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to NewsVine - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Fark - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Furl - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Shadows - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to YahooMyWeb - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Reddit -Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to StumbleUpon - Barr confirms patent challenge of Prevacid SoluTab tablets Add our medical news to Facebook - Barr confirms patent challenge of Prevacid SoluTab tablets

How Software Patents' Fuzzy Boundaries Create Unnecessary Litigation

James Bessen and Michael Meurer, authors of an important new book on the patent system, have a great post on the problems created specifically by software patents. They argue that the most serious problem with software patents is that they tend to cover abstract concepts rather than specific physical devices or processes. As a result, the boundaries of software patents tend to be uncertain, leading to a lot of litigation. In many areas of patent law, the "enablement" rule (which says that patent applications have to describe an invention in enough detail to "enable" someone to replicate it) helps to ensure more precise definition of patent boundaries. But the patent office only requires a general description of an "invention's" functionality to get a software patent.

Barr confirms Entocort patent challenge

Add our medical news to digg - Barr confirms Entocort patent challenge Add our medical news to NewsVine - Barr confirms Entocort patent challenge Add our medical news to Fark - Barr confirms Entocort patent challenge Add our medical news to Furl - Barr confirms Entocort patent challenge Add our medical news to Shadows - Barr confirms Entocort patent challenge Add our medical news to YahooMyWeb - Barr confirms Entocort patent challenge Add our medical news to Reddit -Barr confirms Entocort patent challenge Add our medical news to StumbleUpon - Barr confirms Entocort patent challenge Add our medical news to Facebook - Barr confirms Entocort patent challenge

EntreMed receives new patent for 2-Methoxyestradiol analogs

Add our medical news to digg - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to NewsVine - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Fark - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Furl - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Shadows - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to YahooMyWeb - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Reddit -EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to StumbleUpon - EntreMed receives new patent for 2-Methoxyestradiol analogs Add our medical news to Facebook - EntreMed receives new patent for 2-Methoxyestradiol analogs

Mylan wins generic Prilosec patent litigation

Add our medical news to digg - Mylan wins generic Prilosec patent litigation Add our medical news to NewsVine - Mylan wins generic Prilosec patent litigation Add our medical news to Fark - Mylan wins generic Prilosec patent litigation Add our medical news to Furl - Mylan wins generic Prilosec patent litigation Add our medical news to Shadows - Mylan wins generic Prilosec patent litigation Add our medical news to YahooMyWeb - Mylan wins generic Prilosec patent litigation Add our medical news to Reddit -Mylan wins generic Prilosec patent litigation Add our medical news to StumbleUpon - Mylan wins generic Prilosec patent litigation Add our medical news to Facebook - Mylan wins generic Prilosec patent litigation

Biopure Corporation wins European patent challenge

Add our medical news to digg - Biopure Corporation wins European patent challenge Add our medical news to NewsVine - Biopure Corporation wins European patent challenge Add our medical news to Fark - Biopure Corporation wins European patent challenge Add our medical news to Furl - Biopure Corporation wins European patent challenge Add our medical news to Shadows - Biopure Corporation wins European patent challenge Add our medical news to YahooMyWeb - Biopure Corporation wins European patent challenge Add our medical news to Reddit -Biopure Corporation wins European patent challenge Add our medical news to StumbleUpon - Biopure Corporation wins European patent challenge Add our medical news to Facebook - Biopure Corporation wins European patent challenge

VocalTec Communications To Sell Patents For $12.5 Million

May 28, 2008 (FinancialWire) VocalTec Communications Ltd. (NASDAQ: VOCL) (Current Market Cap. US$3.84 Mil.) has signed a patent purchase agreement to sell selected patents to Karo Millennium J.P. L.L.C. Other companies trading in VocalTec s industry include AT&T Inc. (NYSE: T), Verizon Communications Inc. (NYSE: VZ), an BCE Inc. (NYSE: BCE). Pursuant to the PPA, VocalTec will sell 11 patents and certain patent-related rights, out of the company s current portfolio of 22 patents, for the aggregate selling price of $12.5 million. The patents to be sold consist of nine US patents, one Israel patent, and one Australian patent. Consummation of the transaction is subject to certain conditions, including approval of the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor.

Environmental Control Corporation Acquires Second Canadian Patent

VANCOUVER, BC -- 05/20/08 -- Environmental Control Corporation ("EVCC") (OTCBB: EVCC) -- It is with great pleasure that Environmental Control Corporation ("EVCC") (OTCBB: EVCC) announces the approval of its second Canadian Patent. The Reverse Flow Catalytic Muffler, Canadian Patent # 2,448,648, now accompanies Canadian Patent # 2,448,742 -- The Combined Catalytic Muffler. Other intellectual property currently held by EVCC includes two U.S. Patents: The Reverse Flow Catalytic Muffler (U.S. Patent # 7,018,590) and The Combined Catalytic Muffler (U.S. Patent # 6,622,482); and one pending patent in Europe: the Reverse Flow Catalytic Muffler (Patent Application # 02742591.7). It is anticipated that the European patent application will be approved and registered in the near future.

U.S. Patent Office Allows Another Significant VNUS Patent

SAN JOSE, Calif., May 9 /PRNewswire-FirstCall/ -- VNUS(R) Medical Technologies, Inc. today announced that the U.S. Patent & Trademark Office has decided to allow a second continuation patent application related to the patents in the VNUS patent infringement lawsuit against suppliers of endovenous laser products. This comes on the heels of the Patent Office's decision last month to allow VNUS a separate patent application, also filed as a continuation of one of the patents in the lawsuit.

Search took 0.90 seconds.